TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00281190

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage during indicated bronchoscopy
Description: A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
Study: NCT02961049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total-etch adhesive system
Description: Two layers of pirmer/bond on enamel and dentin with a brush.
Study: NCT03084029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 international units

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 international units

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 international units
Study: NCT02961049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total-etch adhesive system
Description: Two layers of pirmer/bond on enamel and dentin with a brush.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-conditioning adhesive system
Description: One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
Study: NCT02961049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-conditioning adhesive system
Description: One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
Study: NCT02188498

Intervention type: PROCEDURE
Intervention: Polysomnography
Description: Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
Study: NCT02804308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Training
Study: NCT00364533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (CG5503)
Description: Fixed Dose 50, 75, \& 100 mg BID for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fixed Dose Matching placebo for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCL IR
Description: Fixed Dose 10 mg BID for 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Tapentadol IR (CG5503)
Description: Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
Study: NCT00254540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248 capsule
Description: 50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
Study: NCT05633524

Intervention type: OTHER
Intervention: blood sample analysis
Description: All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed

Intervention type: OTHER
Intervention: blood sample analysis
Description: All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
Study: NCT04533308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation in virtual reality
Description: Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
Study: NCT00319917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study: NCT01702740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg/kg CNTO 136
Description: Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg/kg CNTO 136
Description: Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT00319917

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT01714154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: 200 mg orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: 200 mg orally every 12 hours
Study: NCT02989740

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
Study: NCT00082355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (Activase, Genentech)
Description: Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
Study: NCT04371887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Tailoring
Description: The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants.
Study: NCT02940847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique
Description: It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique
Description: Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
Study: NCT01572233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity and Psycho-Education (PPAPE) Program
Description: 1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment.
Study: NCT03590054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV on day 1 of every 21 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV on day 1 of every 21 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV on day 1 of every 21 day cycle
Study: NCT00799825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Description: All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
Study: NCT03916757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-Boost
Description: Open label setting
Study: NCT01702740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg CNTO 136
Description: Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT00995683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half molar sodium lactate
Description: intravenous infusion of 0.5 ml/kg during 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic sodium chloride
Description: intravenous infusion of 0.5 ml/kg during 48 hours
Study: NCT03146845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEVYN Life Non-Bordered
Description: Foam Dressing
Study: NCT01053364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NL-Prow interspinous spacer implant
Description: Interspinous spacer implant
Study: NCT01254227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox and Deferoxamine
Study: NCT04146025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Coach Intervention
Description: 1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach.
Study: NCT03585179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tranexamic Acid
Description: Participants will take a pill of 250 mg bid for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% topical tranexamic acid
Description: Participants will apply a layer of gel on the affected skin bid for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% hydroquinone
Description: Participants will apply a layer of cream on the affected skin once at night
Study: NCT04103762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: systematic intraoperative cholangiography
Description: systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: systematic intraoperative cholangiography
Description: systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
Study: NCT00824044

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
Study: NCT03092973

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Study: NCT01702740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT01328340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-speed power training
Description: exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow-speed strength training
Description: exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
Study: NCT02145871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard fluid management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid management guided by the EV1000
Study: NCT01958853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy
Study: NCT02961049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photoactivated
Description: Photoactivated for 20 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photoactivated
Description: Photoactivated for 20 seconds
Study: NCT02117635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX DP
Description: 20 million cell dose administered by surgery to the damaged area of the brain
Study: NCT01394887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg of metformin twice daily over 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 850 mg gel capsules with starch (6.8 calories)as placebo
Study: NCT01480011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactobacillus CD2 lozenges
Description: The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
Study: NCT02715726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for alirocumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for ezetimibe
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01448005

Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
Study: NCT00797238

Intervention type: OTHER
Description: No intervention in this study
Study: NCT02360293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay Strong w/coaching
Description: Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stay Strong
Description: Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
Study: NCT02410265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lantern: Guided self-help program
Description: Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Online: Self-help program
Description: Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
Study: NCT01859845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research.
Study: NCT00895960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (Radiotherapy)
Description: As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ (Temozolomide)
Description: 75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
Study: NCT05462808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High viscosity glass ionomer cement
Description: High viscosity glass ionomer cement
Study: NCT03146845

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Care
Description: Foam Dressing
Study: NCT01347294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Intralesional

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrovein
Description: Intralesional

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin + Fibrovein
Description: Intralesional
Study: NCT02652845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Engagement Program
Description: This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
Study: NCT02322645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone Tablets 3 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone Tablets 3 mg
Study: NCT02203656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: protein supplement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home exercise
Description: In-home exercise program
Study: NCT01680835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverFlex™ Self-Expanding Peripheral Stent System
Description: Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
Study: NCT02291640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: video laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: video laryngoscopy
Study: NCT01396915

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Protein Intake
Description: Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
Study: NCT04335539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study: NCT02646761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterACTION
Description: InterACTION guided home exercise program paired with standard of care physical therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Physical Therapy
Description: Physical therapy rehabilitation program